Form 4: Boston Scientific Director Cathy Smith Receives Equity Grant

Boston Scientific Corp. director Cathy R. Smith was granted 879 deferred stock units as part of her compensation package, including an initial equity award and units in lieu of cash.

Summary

• Cathy R. Smith, a Director of Boston Scientific Corp. (BSX), acquired 879 Deferred Stock Units (DSUs).
• The DSUs were granted on March 2, 2026.
• 556 DSUs represent a prorated equity award valued at approximately $42,419.50.
• 323 DSUs were granted in lieu of 100% yearly cash compensation, valued at approximately $24,662.50.
• Both grants are prorated for the period from her initial appointment to the Board until the Company's 2026 annual meeting of stockholders.
• The deferred stock units vest in full upon the next annual meeting of stockholders.
• Vested shares will be issued to Ms. Smith following her separation from Board service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard corporate governance practices and aligning director incentives with shareholder interests, without indicating any significant operational or financial shifts.

Positives

• The grant of deferred stock units aligns the director's interests with long-term shareholder value.
• The compensation structure includes an equity component, which is a common best practice for non-employee directors.

Future Outlook

The filing indicates that the deferred stock units will vest upon the Company's 2026 annual meeting of stockholders, aligning future compensation with company performance up to that point.

Management Comments

• Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
• Grant of deferred stock units to non-employee director following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2026 annual meeting of stockholders.
• Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

Industry Context

StockSavvy.ai notes that granting equity-based compensation, such as deferred stock units, to non-employee directors is a standard practice across the medical device and broader corporate sectors. This approach aims to align the interests of directors with long-term shareholder value, a common governance principle.

Comparison to Industry Standards

• StockSavvy.ai observes that the structure of non-employee director compensation at Boston Scientific, involving prorated equity awards and the option to receive compensation in deferred stock units, is consistent with practices seen in comparable large-cap medical technology companies such as Medtronic (MDT) or Abbott Laboratories (ABT).
• While specific compensation amounts vary, the use of DSUs vesting at the next annual meeting and issued upon separation from service is a widely adopted model to ensure long-term commitment and alignment.

Corporate Governance

Related Party Transactions

• Grant of 879 deferred stock units to Cathy R. Smith, a non-employee director, as part of her compensation.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's long-term interests with shareholder value.
• Directors: Provides compensation to a non-employee director, reflecting their contribution to the Board.

Next Steps

• The deferred stock units will vest in full upon the Company's 2026 annual meeting of stockholders.
• Vested shares will be issued to Cathy R. Smith following her separation from Board of Director service.

Key Dates

Recommendation

This Form 4 filing details a routine compensation grant to a non-employee director and does not contain information that would significantly alter the investment thesis for Boston Scientific. It reflects standard corporate governance and compensation practices, thus warranting a 'hold' recommendation based solely on this filing.

Keywords

Boston Scientific, BSX, Cathy R Smith, Director Compensation, Deferred Stock Units, Equity Grant, SEC Form 4, Insider Transaction, Corporate Governance